Highest-materiality recent filing
HeartCore Q2 net loss $2.0M vs prior-year income; revenue up 71.6% to $321k
Q2 revenue $321k, up 71.6% YoY; gross loss $70k vs $23k loss.
HeartCore sells 51% stake in Vietnam JV to Luvina for JPY 29M
Sold entire 51% ownership in HeartCore Luvina Vietnam to Luvina Software for JPY 29M (~$184,093).
HeartCore divests 51% Sigmaways stake, debt for up to $650k; reduces loss exposure
HeartCore sold 51% stake in Sigmaways and $2.19M in promissory notes for up to $650k ($1k cash + earn-out).
HeartCore Q1 revenue down 43% to $1.2M; net loss narrows to $2.0M
Revenue of $1.2M, down 43% YoY from $2.1M due to decline in software development and services.
HeartCore regains Nasdaq minimum bid price compliance, listing continues
Received Nasdaq notice on April 20, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
HeartCore Enterprises executes 1-for-20 reverse stock split, effective April 2, 2026
Board approved 1-for-20 reverse stock split on March 4, 2026; effective for state law at 4:00 PM ET on April 2, 2026.
HeartCore Enterprises announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split ratio set at 1-for-20; effective April 2, 2026 at 4:00 p.m. ET.
HeartCore FY2025 rev $9.0M (-60% YoY); net income $5.5M on gain from divestiture
Revenue $9.0M vs $22.7M YoY; prior year included $13M warrant revenue from a large Go IPO deal.
HeartCore amends bylaws to clarify attorneys' fees provision excludes internal corporate claims
Board adopted amendment to Section 7.4 of Bylaws on March 24, 2026.
HeartCore authorizes $2M share repurchase; net assets exceed market cap
Board authorized repurchase of up to $2.0M of common stock via open market, private deals, or 10b5-1 plans.
Revenue expected $8.5M-$9.5M, down YoY due to divestiture of HeartCore Japan; prior year net loss of $5.2M.
HeartCore Q3 revenue falls to $3M, net income $0.4M after divesting software unit
Q3 2025 revenue $3.0M vs $16.2M prior year; prior year included $13M warrant revenue from large Go IPO deal.
HeartCore gets 180-day Nasdaq extension to May 1, 2026 for $1 minimum bid compliance
Nasdaq granted until May 1, 2026 to regain $1.00 minimum bid price compliance; prior deadline was Nov 3, 2025.
HeartCore clarifies post-sale equity over $5M; shifts strategy to Go IPO consulting
Sale of HeartCore Japan closed Oct 31 for ¥1.8B (~$12M), with deferred consideration of ¥387M at 6.65% interest due Oct 2028.
HeartCore sells software subsidiary for ~$12M; shifts to Go IPO consulting
Sold HeartCore Japan to Volaris Group for ¥1.8B (~$12M) in all-cash; closed Oct 31, 2025.
One-time payment of $0.13/share classified as a distribution for U.S. federal tax purposes, correcting earlier dividend statement.
HeartCore declares $0.13/share one-time dividend, ~17.8% of stock price, payable Nov 17
One-time dividend of $0.13 per share authorized by Board on October 19, 2025.
HeartCore stockholders elect five director nominees and ratify auditor at 2025 annual meeting
All five nominees elected: Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Yoonji Lee, Koji Sato.
HeartCore regains Nasdaq minimum equity compliance after Q2 equity of $3.56M
Nasdaq notified HeartCore on Aug 19, 2025 that it regained compliance with the $2.5M minimum stockholders' equity rule.
HeartCore announces Go IPO client rYojbaba begins Nasdaq trading; warrants valued at ~$1.35M
rYojbaba (RYOJ) commenced trading on Nasdaq Capital Market on August 18, 2025.
Director Heather Neville resigns effective September 1, 2025; not due to any disagreement.
HeartCore returns to profitability with Q2 net income $1.1M; revenue up 16.7%
Revenue $4.7M (+16.7% YoY); gross profit $2.2M (+175.2%).
Nasdaq granted extension until September 30, 2025 to regain compliance with $2,500,000 minimum stockholders' equity requirement.
Equity Purchase Agreement with Crom for up to $25M in common stock (ELOC); $250K commitment fee in shares.
HeartCore signs 16th Go IPO consulting agreement with Cipher Core for $500K plus warrant
Cipher Core will pay $500,000 in fees plus a warrant for 3% of its fully diluted capital stock.
HeartCore secures up to $27M financing: $25M equity line + $2M convertible preferred from Crom Fund
Equity Purchase Agreement: HeartCore may sell up to $25M of common stock to Crom over 24 months at a discount of 50% of average daily trading volume.
HeartCore partners with Silver Egg to integrate AI recommend engine into CMS by Aug 2025
OEM agreement signed June 23, 2025, with Silver Egg for its 'Aigent Recommender' AI recommendation service.
HeartCore signs 15th Go IPO consulting contract with tmsuk; $500k fee plus 3% warrant
Cash fee of $500,000 payable in three installments: $200k at signing, $150k at 3 months, $150k at 6 months.
Received Nasdaq Staff notice on May 24, 2025 for non-compliance with $2.5M minimum stockholders' equity requirement (Rule 5550(b)).
HeartCore Q1 revenue falls 28% to $3.6M; net loss widens to $3.1M
Revenue of $3.6M down from $5.0M YoY; on-premise software, Sigmaways, and Go IPO all declined.
HeartCore receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Received Nasdaq written notice on May 6, 2025 for failure to meet $1.00 minimum bid price requirement.
HeartCore reports 2024 revenue up 39% to $30.4M; net loss attributable improves
FY2024 revenue $30.4M (+39% YoY); gross profit $17.8M (+121% YoY).
HeartCore loses controlled company status; forms compensation and nominating committees
Sumitaka Yamamoto's voting power fell below 50% after ATM sales, triggering loss of controlled company status.
HeartCore furnishes investor presentation; no specific details disclosed in filing
Management will deliver an investor presentation starting November 15, 2024.
HeartCore Q3 revenue $17.9M (+281% YoY), net income $10.8M vs loss a year ago
Q3 revenue $17.9M (+281% YoY); net income $10.8M ($0.53 diluted EPS) vs net loss of $2.5M a year ago.
HeartCore regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq notice on Nov 5, 2024 confirming compliance with $1.00 minimum bid price requirement.
HeartCore corrects press release: sales growth projection lowered from 115% to 15%
HeartCore expanded its CMS platform to a SaaS delivery model, leveraging AWS infrastructure.
HeartCore to appeal Nasdaq delisting; preliminary Q3 revenue up 263-305% YoY
Received Nasdaq notice on Oct 22, 2024 for non-compliance with $1 minimum bid price; trading suspended Oct 31 if no appeal.
HeartCore receives Nasdaq delisting notice for bid price non-compliance; intends to appeal
Received Oct 22, 2024 Nasdaq notice for failure to maintain $1.00 minimum bid price for continued listing.
HeartCore preliminary Q3 2024 revenue $17-19M vs $4.7M YoY; net income $9-11M vs loss of $2.5M
Revenue expected $17-19M, up 263-305% YoY; net income $9-11M vs $2.5M loss in Q3 2023.
HeartCore shareholders approve reverse stock split authorization at 2024 annual meeting
Six directors elected: Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Heather Neville, Prakash Sadasivam, Koji Sato.
SBC Medical Group begins trading on Nasdaq; HeartCore guides Q3 rev $19-23M, net profit $4-8M
Go IPO client SBC Medical Group commenced trading on Nasdaq Global Market under symbol 'SBC'.
HeartCore Enterprises projects FY2024 revenue of $46.6M, subject to IPO timing
Projected full-year 2024 revenue of $46.6 million, contingent on Go IPO client IPO timing.
HeartCore Q2 revenue down 20% to $4.1M, net loss widens to $2.2M; dividend authorized
Net loss of $2.2M ($0.09 diluted EPS) vs net loss of $1.0M ($0.04) in Q2 2023.
HeartCore declares $0.02 per share quarterly dividend, second payment
Second dividend of $0.02 per share, aggregate $417,283; record date Aug 19, payable Aug 26, 2024.
HeartCore Q1 revenue $5.0M (down 43% YoY); net loss $1.5M vs prior year net income $1.8M
Revenue $5.0M vs $8.7M YoY; decline due to lower Go IPO consulting from two clients listing on Nasdaq last year.
HeartCore updates on $9M warrant sale; cash received, revenue deferred until client IPO in Fall 2024
Gross $9M from sale of Go IPO warrant to Japanese financial institution; $5M received Q1 2024, $4M in April.
HeartCore gets Nasdaq extension to Oct 21, 2024 to cure bid price deficiency
Received Bid Price Notice Oct 26, 2023 for non-compliance with $1.00 minimum bid price.
HeartCore signs 14th Go IPO contract with Koei Shoji; $500K fees plus 3% warrant
Signed consulting agreement with Koei Shoji Co., Ltd. to assist in U.S. listing on Nasdaq or NYSE.
Revenue $21.8M (+148% YoY); gross profit $8.1M (+140.7%); net loss $4.9M ($0.21/diluted share).
On November 2, 2023, Yoshitomo Yamano resigned as a member of the Company's Board of Directors, effective immediately.
Also on September 29, 2023, the Company entered into an Independent Director Agreement (the “Director Agreement”) with Mr. Sato.
expanded the size of the Board from eight persons to nine persons, and named Heather Marie Neville to serve as a member of the Board
the Board expanded the size of the Board from seven persons to eight persons, and named Mr. Sadasivam to serve as a member of the Board
On February 1, 2023, Mr. Sadasivam was appointed to serve as the Company’s Chief Strategy Officer.
On February 1, 2023, Mr. Sadasivam was appointed to serve as the Company’s Chief Strategy Officer.
In addition, on February 1, 2023, the Board expanded the size of the Board from seven persons to eight persons, and named Mr. Sadasivam to serve as a member of the Board, to fill the vacancy created by the increase in the size of the Board.
Mr. Sadasivam was appointed to serve as the Company's Chief Strategy Officer.
the Board expanded the size of the Board from seven persons to eight persons, and named Mr. Sadasivam to serve as a member of the Board
Max materiality 0.85 · Median 0.65 · Most common event other_material